Corvus Pharmaceuticals, Inc.
NASDAQ:CRVSBiotechnology
Healthcare
$10.19 -1.58%
-$0.19 today
- Market cap
- $859.56M
- Beta
- 0.84
- P/E (TTM)
- -24.1
- EPS (TTM)
- -$0.49
52W Low $3.55High $26.95
Volume 0.99M
Average 1.49M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$32.80M
FY 2025 · Annual
Investing Cash Flow
-$7.80M
FY 2025 · Annual
Financing Cash Flow
$36.43M
FY 2025 · Annual
-25.7% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (43.24M) | (41.31M) | (27.03M) | (62.29M) | (15.28M) |
| Depreciation & Amortization | 460K | 367K | 151K | 85K | 105K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.23M | 2.69M | 2.15M | 3M | 5.33M |
| Change in Working Capital | (3.24M) | 1.41M | (3.59M) | (1.65M) | 3.58M |
| Accounts Receivables | (507K) | (81K) | 562K | (49K) | 38K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (1.9M) | 411K | (451K) | 1.06M | (91K) |
| Other Working Capital | (827K) | 1.08M | (3.71M) | (2.66M) | 3.63M |
| Other Non-Cash Items | 5.07M | 9.81M | 4.39M | 35.43M | (26.53M) |
| Operating Cash Flow | (36.72M) | (27.02M) | (23.94M) | (25.42M) | (32.8M) |
| Capital Expenditures | (5K) | (269K) | (34K) | 0 | (174K) |
| Acquisitions (Net) | (21.57K) | 22K | 0 | 5K | 0 |
| Purchases of Investments | (9.36M) | (66.19M) | (47.05M) | (70.12M) | (91.75M) |
| Sales of Investments | 30.92M | 43.16M | 62.62M | 42.63M | 84.13M |
| Other Investing Activities | 21.57K | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 21.56M | (23.28M) | 15.54M | (27.48M) | (7.8M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 60.94M | 0 | 7.84M | 16.41M | 36.43M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.22M | 0 | 12K | 32.62M | 0 |
| Financing Cash Flow | 62.16M | 0 | 7.86M | 49.03M | 36.43M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 47M | (50.3M) | (539K) | (3.88M) | (4.16M) |
| Free Cash Flow | (36.72M) | (27.29M) | (23.97M) | (25.42M) | (32.97M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$15.3M
+ D&A$105.0K
+ Stock-Based Comp$5.3M
+ Deferred Tax$0
+ Working Capital$3.6M
- Other Non-Cash-$26.5M
= Operating Cash Flow-$32.8M
- Capex-$174.0K
= Free Cash Flow-$33.0M
Analysis
FY2025 free cash flow is -$33.0M. FCF conversion is 215.7% of net income. Operating cash flow was -$32.8M, with capex of -$174.0K. The largest bridge item is Other Non-Cash at -$26.5M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Nov 13, 2026 | |
| SC 13G | SC 13G filing | Nov 10, 2026 | |
| 10-Q | Quarterly report | Nov 5, 2026 | |
| 8-K | Current report | Nov 5, 2026 | |
| SC 13G | SC 13G filing | Aug 7, 2026 |
Does CRVS generate free cash flow?
Corvus Pharmaceuticals, Inc. (CRVS) generated -$32.97M of free cash flow in fiscal 2025.
How much operating cash flow does CRVS produce?
Operating cash flow was -$32.80M, before capital expenditures of $174,000.00.
Continue the stock analysis
Jump to another research area for this company.